Apollomics Inc. Trials Uproleselan for Acute Myeloid Leukemia
Apollomics Inc. has recently shared the outcomes of its pivotal Phase 3 trial assessing uproleselan in patients suffering from relapsed or refractory acute myeloid leukemia (AML). Although the company aimed to advance treatment options for this challenging condition, the results revealed that uproleselan did not demonstrate a significant benefit compared to conventional chemotherapy.
Study Overview and Efficacy Results
This Phase 3 trial implemented a randomized, double-blinded design where participants received either uproleselan in combination with chemotherapy or chemotherapy alone. A total of 140 patients entered the study, evenly allocated to each treatment group. The primary goal was to evaluate overall survival rates as the main measure of effectiveness.
Results showed that patients receiving uproleselan combined with chemotherapy had a median overall survival of 9.3 months, compared to 14.3 months for those on chemotherapy alone. This outcome did not meet the anticipated criteria for a successful intervention, as signified by a p-value of 0.48, suggesting no significant statistical difference in survival outcomes.
Safety Profile and Adverse Events
In terms of safety, the addition of uproleselan was generally tolerated well, exhibiting a similar safety profile when compared to the control group. However, there was a notable incidence of serious adverse events, occurring in 43% of patients receiving uproleselan versus 39% in the chemotherapy-only cohort. Among these, the most frequently observed were decreased platelet counts, infectious pneumonia, and instances of sepsis.
Company Response and Future Directions
Expressing disappointment, Dr. Guo-Liang Yu, Chairman and CEO of Apollomics, noted that the results were not unexpected, especially following similar outcomes from a global Phase 3 trial conducted by their partner, Glycomimetics. Due to these findings, Apollomics has indicated that it is moving to conclude this particular clinical program, emphasizing the importance of positive results from the global trial to its regulatory strategy in China.
In a related announcement made earlier, Apollomics indicated that it had written down an intangible asset connected to the upfront payment for the uproleselan program, forecasting that future expenses linked to this program would not exceed $500,000.
About Apollomics Inc.
Apollomics is a forward-thinking clinical-stage biopharmaceutical entity devoted to developing groundbreaking oncology therapies. The company’s main focus lies in innovating treatments that can work synergistically with existing therapies, aiming to leverage the immune system and alternative pathways to combat cancer effectively. Their flagship program, vebreltinib (APL-101), is currently being evaluated in a Phase 2 multicohort trial across the United States and more than ten other countries.
Frequently Asked Questions
What are the main findings of the Phase 3 trial conducted by Apollomics?
The trial indicated that the addition of uproleselan to chemotherapy did not significantly improve overall survival rates compared to chemotherapy alone.
What safety concerns were raised during the trial?
The trial reported serious adverse events in 43% of the uproleselan group with notable issues including decreased platelet count, pneumonia, and sepsis.
What is the next step for Apollomics following these trial results?
Apollomics plans to conclude the current program and focus on the findings from this and other related trials as they assess their next steps.
How is Apollomics positioning itself in the oncology market?
Apollomics is focusing on creating innovative oncology therapies that can work in conjunction with other treatments to provide enhanced care for cancer patients.
Who can I contact for investor inquiries regarding Apollomics?
For investor-related questions, Eric Ribner of LifeSci Advisors at (646) 751-4363 is available for assistance.
